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Aims To examine a relationship between alterations of structure and function of the arterial wall in response to glucose-
lowering therapy in type 2 diabetes mellitus (DM) after a 1-year follow-up (FU).
Methods
and results
In DM (n ¼ 22) and in healthy controls (n ¼ 17), coronary artery calcification (CAC) was assessed with electron
beam tomography and carotid intima–media thickness (IMT) with ultrasound, whereas coronary function was deter-
mined with positron emission tomography-measured myocardial blood flow (MBF) at rest, during cold pressor
testing (CPT), and during adenosine stimulation at baseline and after FU. The decrease in plasma glucose in DM
after a mean FU of 14+1.9 months correlated with a lower progression of CAC and carotid IMT (r ¼ 0.48,
P  0.036 and r ¼ 0.46, P  0.055) and with an improvement in endothelium-related DMBF to CPT and to adenosine
(r ¼ 0.46, P  0.038 and r ¼ 0.36, P  0.056). After adjusting for metabolic parameters by multivariate analysis, the
increases in DMBF to CPT after glucose-lowering treatment remained a statistically significant independent predictor
of the progression of CAC (P  0.001 by one-way analysis of variance).
Conclusion In DM, glucose-lowering treatment may beneficially affect structure and function of the vascular wall, whereas the
observed improvement in endothelium-related coronary artery function may also mediate direct preventive
effects on the progression of CAC.
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Introduction
Type 2 diabetes mellitus (DM) is accompanied by the early devel-
opment of accelerated coronary artery disease (CAD) that
accounts for excess morbidity and mortality in these patients.1
According to the American Diabetes Association, there is a con-
tinuous increase in the prevalence of DM and, therefore, poses a
considerable public health concern.1 Subclinical measures of
CAD such as coronary circulatory dysfunction,2,3 increased
carotid intima–media thickness (IMT),4 a surrogate marker for
subintimal CAD process, and coronary artery calcification
(CAC)5 have all been shown to independently predict the develop-
ment of CAD and future cardiovascular events.2,5 Diabetes melli-
tus induces structural and functional alterations of the arterial
wall, which are associated with pro-atherosclerotic and pro-
thrombotic effects, and provide an important mechanistic link
between early stages of vascular disease and adverse cardiovascu-
lar outcome in DM.2
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As we have shown previously,6 a progressive worsening of cor-
onary artery function parallels the increasing severity of insulin
resistance states and of carbohydrate intolerance, which can be
reversed or be ameliorated by glycaemic control,7 which in turn
may slow the development of diabetic vasculopathy.8 The effects
of glucose-lowering on both, structure and function of the arterial
wall, however, have not been evaluated concurrently in patients
with DM. Apart from direct adverse effects of cardiovascular risk
factors on the arterial wall, functional abnormalities of the coron-
ary circulation, associated with a loss of endothelium-derived and
atheroprotective nitric oxide, have been widely realized to initiate
and promote atherosclerotic disease.2 Therapy-induced improve-
ments of endothelium-dependent coronary artery function might
therefore delay the development of structural changes of the
arterial wall.
Herein, we intended to evaluate (i) the effects of glucose-
lowering treatment on CAC, increased carotid IMT, and coronary
artery function in patients with DM, and (ii) a possible association
between an improvement in coronary artery function and the rate
of progression of structural alterations of the arterial wall.
Methods
Study population
The study population consisted of 17 healthy controls [CON; 9 male, 8
female; mean [standard deviation (SD)] age 39+13 years] and 22
asymptomatic type 2 diabetes mellitus patients (DM; 10 male, 12
female; mean age 53+7 years) (Tables 1 and 2). Inclusion criteria
were, at the time of the initial screening visit, the presence of DM diag-
nosed by standard criteria. Exclusion criteria included a history of cor-
onary or peripheral vascular disease, prior myocardial infarction,
hypercholesterolaemia (total plasma cholesterol 240 mg/dL and
LDL plasma cholesterol 155 mg/dL), chronically elevated blood
pressure (140/90 mmHg) measured on at least two occasions,
current or prior smoking, a family history of premature CAD, and
any endocrine, hepatic, renal, or inflammatory disease. The presence
of DM was established by standard clinical criteria and confirmed at
the time of the screening visit by fasting plasma glucose concentrations
of .126 mg/dL on at least two occasions and elevated HbA1c
concentrations.7 All study participants were normal on physical exam-
ination and had normal electrocardiograms at rest. The patients
reported a mean duration of their diabetes of 25+16 months
(range 3–48). These DM were not on anti-diabetic treatment or any
other medications before study recruitment and at baseline examin-
ations. Before study inclusion, DM patients tried to control diabetes
by diet, weight loss, and physical activity. Twenty out of these 22
DM as well as 17 CON were part of a previous investigation assessing
the short-term effect of euglycaemic control on coronary artery
function.7
Study protocol
Diabetic patients considered eligible to participate in the study did
meet with the physician and the diabetes nurse 2 weeks before
start of glucose-lowering treatment with glyburide and/or metfor-
min. Subsequently, after the baseline measurements of CAC using
electron beam tomography (EBT), carotid IMT with high-resolution
vascular ultrasound and myocardial blood flows (MBFs) at rest and
during vasomotor stress with N-13 ammonia positron emission
tomography (PET) were obtained in DM, and glucose-lowering
treatment with glyburide was started. Treatment was commenced
with oral glyburide at a dose of 10 mg/day. If, after 10 days,
fasting glucose concentrations remained .126 mg/dL, the dose
was increased to 10 mg twice a day (total of 20 mg/day). If, after
an additional 20 days, no euglycaemic control (plasma glucose
126 mg/dL) was achieved, metformin at a dose between 500
and 1000 mg (maximal dose of 1000 mg/day) was added to the gly-
buride. A medium dose of glyburide and/or metformin was applied
as it yields 80% of the glucose-lowering effect and, the same time,
minimizes potential side effects such as hypoglycaemic events.
Patients and immediate family members were instructed to
contact one of the investigators in instances of hypoglycaemia or
other adverse reactions. The diabetic patients visited the hospital
outpatient clinic after start of the glucose-lowering treatment at
4-month intervals. The follow-up (FU) measurements of CAC,
carotid IMT, MBF and blood chemistry function test were per-
formed after the outpatient visit after at least 12 months. Positron
emission tomography flow measurements and blood chemistry func-
tion test at baseline and FU were performed in the morning at
fasting condition, whereas measurements of CAC and carotid IMT
took place on the same day in the afternoon. A subgroup of dia-
betic responders was defined as those DM who did demonstrate
a decrease in plasma glucose after the FU when compared with
baseline.
Evaluation of coronary artery calcium
Coronary artery calcification was determined with EBT (GE Imatron,
Milwaukee, WI, USA). Two prospective cardiac-gated (at 60% R–R
interval) scans were acquired using 3 mm collimation CVS mode. Uti-
lizing the Accu-Image workstation, areas of CAC were considered to
be present, if hyperattenuating lesions above a threshold of 130
Hounsfield units (HU) with an area of three or more contiguous
pixels (at least 1 mm2) were identified.9 The size of the lesion was
automatically calculated, and the CAC was scored using the Agatston
algorithm.9 The coronary artery calcium score (CCS) was assessed
across all lesions within the left main, left anterior descending, left cir-
cumflex, and right coronary artery, and the sum of all lesion scores
yielded the total CCS. An abnormal CAC was defined as a CCS
.75th percentile of age-related CAC. Based on the total CCS,
study participants were assigned into groups of minor, moderate, or
severe CAC with CCS of 100, .100 and ,400, and 400 U,
respectively.9
Determination of carotid intima–media
thickness
Using a high-resolution B-mode ultrasound machine (ATL Ultramark
IV, Bothell, WA, USA), images of the common carotid artery were
acquired with a 10 MHz linear array transducer. Carotid IMT was
assessed using an automated computerized edge detection algor-
ithm. Measurements of the right and left common carotid arteries
were performed between the intima–lumen and media–adventitia
interfaces along a 1 cm length just distal to the carotid bulb. This
approach standardizes the location and distance over which
carotid IMT is determined and ascertains that the same portion of
the arterial wall is measured in each image and across individual
persons.10 The reported IMT (in mm) for each study participant
represented the average of 10 measurements (5 measurements
from the right and 5 from the left common carotid artery).
Measurements were obtained by an experienced vascular sonogra-
pher (Y.L.) who was blinded to the clinical and laboratory profile
of the study participants.
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Table 1 Demographics and laboratory findings in normal controls, the whole group of type 2 diabetic patients, and diabetic responders
Controls Diabetes Diabetes responders
Baseline 1-year follow-up Baseline 1-year follow-up Baseline 1-year follow-up
Number, n 17 17 22 22 15 15
Age (years) 39+13 — 53+7* — 53+6* —
Body mass index (kg/m2) 26.8+3.17 26.8+3.34 28.9+3.64 29.1+3.60 29.3+3.3* 29.9+3.27
HbA1c (%) 5.5+0.2 5.3+0.5 9.83+2.7* 8.48+1.91† 10.6+2.9* 8.4+2.07†
Fasting plasma concentrations
Glucose (mg/dL) 84+14 85+11 205+72* 160+44† 231+65* 158+42†
Lactic acid (mg/dL) 13.9+4.1 13.0+3.8 16.3+3.7 16.5+3.8 16.0+3.8 17.1+3.8
Free fatty acids (mmol/L) 0.59+0.26 0.64+0.27 0.77+0.34 0.63+0.23 0.80+0.40 0.59+0.19
Insulin (mU/mL) 8.36+4.34 8.77+6.82 10.9+11.0 13.7+9.5 11.6+13.1 15.2+10.6
HOMA 1.77+1.11 2.00+1.82 5.42+7.07* 5.08+3.17 6.36+8.42* 5.47+3.47
Total cholesterol (mg/dL) 184+28 183+24 208+53 205+41 223+54* 212+36
LDL cholesterol (mg/dL) 114+23 113+20 117+36 119+33 128+33 123+30
HDL cholesterol (mg/dL) 44+11 47+9 45+11 45+10 48+10 45+9
Triglycerides (mg/dL) 123+96 97+42 202+126* 208+ 95 191+122* 220+102
HbA1c, haemoglobin A1c; HOMA, homeostatic model assessment; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*P, 0.05 vs. controls.
†P, 0.05 vs. baseline in diabetes.
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Table 2 Haemodynamic data and myocardial blood flows in normal controls, the whole group of type 2 diabetic patients, and diabetic responders
Controls Diabetes Diabetes responders
Baseline 1-year follow-up Baseline 1-year follow-up Baseline 1-year follow-up
Numbers 17 17 22 22 15 15
CCS (mean, SD) 4.25+9 6.74+19 35.28+68* 59.88+102† 42.7+81* 65.0+121
CCS (median, IQR) 0 (0–0.93) 0 (0–1.40) 3.72 (0–27.1)* 5.12 (0–76.9)† 3.25 (0–27.1)* 4.4 (0–39.0)
IMT (mm) 0.68+0.11 0.70+0.11 0.83+0.19* 0.86+0.18† 0.82+0.20* 0.84+0.19
Haemodynamics
Rest
Heart rate (b.p.m.) 68+9 69+8 71+11 73+14 74+11 76+14
SBP (mmHg) 120+18 116+15 139+21 133+21 139+20* 133+20
RPP (mmHg/min) 8061+1443 7952+1107 9917+2162 9828+2827 10 345+2139* 10 297+2683
MBF (mL/min/g) 0.65+0.14 0.67+0.12 0.77+0.22 0.78+0.17 0.81+0.22* 0.81+0.15
Adenosine-stimulated hyperaemia
Heart rate (b.p.m.) 97+19 97+16 95+15 94+14 99+14 98+14
SBP (mmHg) 119+13 115+13 134+22 131+18 134+20* 132+20
RPP (mmHg/min) 11 579+2395 11 063+1748 12 951+3433 12 442+2956 13 413+3442 13 015+3109
MBF (mL/min/g) 2.02+0.44 2.01+0.39 1.85+0.33 1.97+0.54 1.86+0.40 2.15+0.45†
DMBF (mL/min/g) 1.37+0.41 1.33+0.37 1.08+0.31* 1.19+0.51 1.05+0.35* 1.34+0.44†
MFR 2.97+0.77 3.01+0.67 2.55+0.67* 2.59+0.76 2.38+0.46* 2.72+0.71†
Cold pressor testing
Heart rate (b.p.m.) 76+10 76+10 78+13 79+17 81+13 83+17
SBP (mmHg) 139+23 142+24 164+28 162+20 166+30* 163+19
RPP (mmHg/min) 10 525+2000 10 758+2208 12 767+2998 12 822+3140 13 515+3215* 13 522+3024
MBF (mL/min/g) 0.90+0.21 0.94+0.21 0.86+0.24 0.97+0.26 0.87+0.21 1.04+0.25†
DRPP (mmHg/min) 2464+1540 2805+1465 2849+1850 2995+1482 3169+2123 3225+1740
DMBF (mL/min/g) 0.25+0.12 0.27+0.16 0.09+0.09* 0.19+0.17† 0.07+0.07* 0.23+0.17†
CCS, coronary artery calcium score; SD, standard deviation; IQR, inter-quartile range; IMT, intima–media thickness; SBP, systolic blood pressure; RPP, rate–pressure product (heart rate  systolic blood pressure, b.p.m.  mmHg); MBF,
myocardial blood flow.
*P, 0.05 vs. controls baseline.
†P, 0.05 vs. baseline in diabetes.
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Assessment of coronary artery function with
positron emission tomography
Myocardial blood flow was measured in mL/min/g with N-13 ammonia,
serial PET image acquisition, and a two-compartment tracer kinetic
model as described previously.7 Re-orientated N-13 ammonia per-
fusion images were also evaluated visually and semi-quantitatively for
rest and stress regional perfusion abnormalities. Myocardial blood
flow was measured at rest, during sympathetic stimulation with cold
pressor testing (CPT), reflecting predominantly endothelium-
dependent vasomotion, and during adenosine-stimulated hyperaemia
(140 mg/kg/min adenosine), reflecting predominantly endothelium-
independent vascular smooth muscle relaxation.7 The increase
in MBF from rest to CPT or to adenosine was defined as DMBF
(mL/min/g). The myocardial flow reserve (MFR) was calculated as
the ratio of adenosine MBF over rest MBF. Heart rate, blood pressure,
and a 12-lead electrocardiogram were recorded continuously during
each MBF measurement. The rate–pressure product (RPP), which is
a product of the mean heart rate and systolic blood pressure (SBP)
during the first 2 min of image acquisition, served as an index of
cardiac work.
Statistical analysis
The statistical analysis was performed using SPSS software 11.0 (SPSS
Inc.). Data are presented as mean (SD) for quantitative and absolute
frequencies for qualitative variables. The appropriate Wilcoxon rank
test for independent or paired samples was used. A comparison of
CPT-induced DMBF or adenosine-stimulated hyperaemic MBF or its
change from rest DMBF between the different groups was performed
by one-way analysis of variance (ANOVA), followed by Scheffe’s mul-
tiple comparison test. According to previous investigations,10 an
abnormal increase in carotid IMT was defined as 0.8 mm. Since
CCSs followed a marked skewed distribution, the CCSs were also log-
arithmically transformed (log-CCS). Correlations between selected
variables were estimated by the Spearman correlation coefficients
(r). Multivariable analysis was performed with the logistic regression
model adjusting for the following predictors of the difference in
Dlog-CCS after glucose-lowering treatment: differences in body mass
index (BMI), plasma glucose, homeostasis model assessment
(HOMA), triglycerides, free fatty acids, lipids, and SBP. Statistical
significance was assumed if the null hypothesis could be rejected at
the P  0.05 level. Based on an SD of 7.55 of CCS measurements
with EBT, and a minimum clinically relevant difference in repeat CCS
measurements of 15.8, a ¼ 0.05, and a power (12 b) of 0.8, the
number of patients necessary for repeat long-term studies was calcu-
lated to be at least 10 individuals.11 Similarly, using an SD of 0.18 of
DMBF to vasomotor stress, and a minimum clinically relevant differ-
ence in DMBF of 0.20 in flow response, a ¼ 0.05, and a power (12
b) of 0.8, a minimum sample size of 10 individuals was estimated to
be needed for repeat long-term PET flow studies.12
Results
Baseline studies
Blood chemistry
Plasma glucose levels, HOMA as index for insulin resistance, and
triglycerides were significantly higher in DM than in CON
(Table 1). Total plasma cholesterol, LDL plasma cholesterol, free
fatty acid, and insulin levels tended to be higher in DM than in
the CON, whereas HDL plasma cholesterol was similar.
Coronary artery calcification and carotid intima–media
thickness
For the entire study population, the prevalence of CACs was 56%
(22/39). In CON, CAC was identified in 47% (8/17), which was
non-significantly lower to that of 64% (14/22) of CAC in DM. As
given in Table 2, CCS in DM was observed to be significantly
higher than in CON. The average CCS of 39+67 in the study
population was relatively low. Given the CCS for each patient,
11 DM had minor (100), three had moderate (.100 to
400), and none had severe CCS (.400), whereas 8 CON pre-
sented minor CCS. Further, only four in DM and one in CON
had abnormal increased CCS, when it was related to the age of
the individual study participant (.75th percentile). In the
current study population, no correlation between log-CCS and
the age of the study participants was observed (r ¼ 0.33, P ¼
0.13). As regards the carotid IMT (Table 2), it was abnormally
increased in DM than in CON. When an abnormal increase in
carotid IMT was defined as 0.8 mm according to previous inves-
tigations,10 it was found in 11 of 22 (50%) DM and in 3 of 17 (18%)
CON.
Positron emission tomography measurements of
myocardial blood flow
N-13 ammonia PET rest–stress perfusion images displayed a
homogeneous radiotracer distribution of the left ventricle
arguing against the presence of advanced and flow-limiting coron-
ary lesions. Further, eight DM had blood pressures 140/
90 mmHg at the day of the PET study. At rest, heart rate, SBP,
and RPPs, however, did not differ significantly between CON
and DM (Table 2). Sympathetic stimulation with CPT raised heart
rate and SBP in both groups (Table 2). Despite similar RPP at
rest and during CPT in the two study groups, CPT was associated
with a significantly diminished MBF increase (DMBF) in DM than in
CON (Table 2). Thus, despite comparable increases in cardiac
work with CPT, the increase in endothelium-related coronary
flow was significantly less in DM than in CON (Table 2 and
Figure 1). Further, the adenosine-stimulated hyperaemic MBFs
were associated with a significant increase in heart rates,
whereas a minor decrease in SBP was observed (Table 2). Hyper-
aemic MBFs during adenosine stimulation were lower in DM than
in CON, but it did not reach statistically significance. When the
change in hyperaemic MBF from rest (DMBF) and the MFR were
evaluated, the DMBF during adenosine stimulation and the MFR
in DM were significantly less than in CON.
Follow-up studies after glucose lowering
Clinical characteristics
Type 2 diabetes mellitus patients were treated with glyburide or
glyburide/metformin (mean daily dose of glyburide and metformin:
18+ 4 and 941+ 153 mg, respectively) for at least 12 months
with a mean FU period of 14+1.9 months (range: 12–17),
which did not differ significantly from the mean FU of 15+1.7
months (range: 12–18) in CON (P ¼ 0.43). Eleven DM were on
glyburide treatment only and further 11 DM were on added
therapy with metformin. Only 6 out of 22 (30%) of DM had
achieved euglycaemic control (plasma glucose 126 mg/dL) after
the FU. At FU, plasma glucose and HbA1c concentrations were
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significantly lower than at baseline (Table 1), whereas insulin,
HOMA, triglycerides, free fatty acids, lipids, and SBP had not
changed significantly.
Coronary artery calcification and carotid intima–media
thickness
Possible changes in structural alterations of the arterial wall after
the 1-year FU were evaluated. After the FU, the CCS in DM
was significantly but mildly increased, not observed in CON
(Table 2). Out of 22 DM, 2 patients had new vascular segments
of calcium depositions, whereas in 10 patients, calcium lesions
were identified to be more intense at FU than at baseline investi-
gation. In CON with mild CAC, at FU, no new vascular calcium
depositions were noted, and in two individuals, the CCS had
mildly increased. In both groups of all DM and diabetic responders,
the CCS had non-significantly increased (Table 2). Further, the pro-
gression in CCS from baseline to FU (DCCS) was comparable
between both groups (24.6+ 43 vs. 22.2+ 47; P ¼ 0.87).
As denoted in Table 2, carotid IMT had mildly but significantly
increased in DM, whereas no significant alteration was noted in
CON (Table 1). In the subgroup of diabetic responders, the
carotid IMT tended to be mildly higher at FU than at baseline
(Table 2). Further, the increase in carotid IMT baseline to FU
(DIMT) tended to be higher in the whole group of DM than in
the subgroup of diabetic responders (0.014+0.03 vs. 0.003+
0.02 mm2, P ¼ 0.78).
Positron emission tomography flow measurements
At FU, N-13 ammonia PET rest–stress perfusion images were
normal in all study participants. The endothelium-related increase
in MBF during CPT (DMBF) in DM had significantly improved after
the FU, but still tended to be less than that in CON (Table 2 and
Figure 1). In CON, DMBF to CPT remained comparable between
baseline and FU studies. The group comparison of the increase
in DMBF to CPT in DM after the FU period was significantly
different from CON (P, 0.0001 by ANOVA). The
adenosine-stimulated MBF increases, and its change of MBF from
rest (DMBF) and the MFR in DM at FU tended to be higher than
at baseline (Table 2). In the group of diabetic responders (n ¼
15), hyperaemic MBF during adenosine, DMBF to adenosine stimu-
lation, and MFR were significantly increased at FU than at baseline
(Table 2). In CON, hyperaemic MBF during adenosine, DMBF to
adenosine stimulation, and MFR were not altered between baseline
and FU studies. The group comparison of an increase in hyperae-
mic MBF during adenosine, DMBF to adenosine stimulation, and
MFR in diabetic responders after the FU period was significantly
different from CON (P, 0.0001 by ANOVA).
Comparison of changes in plasma glucose
and structural and functional alterations
of the artery
Alterations in fasting plasma glucose concentrations from baseline
to FU were expressed as the difference in glucose concentrations
at baseline and FU. Changes in glucose concentrations in DM were
compared with those of CCS, carotid IMT, and the improvement in
the flow response to CPT and adenosine stimulation. These
changes were defined as the difference in log-CCS, carotid IMT,
and DMBFs between FU and baseline (e.g. difference
Dlog-CCS ¼ log-CCS baseline2 log-CCS FU).
As regards the structural alterations of the arterial wall, log-CCS
as well as carotid IMT only correlated with the decrease in plasma
glucose concentrations, respectively (r ¼ 0.48, P  0.036 and r ¼
0.46, P  0.05) (Figure 2A and B). Further, the decrease in plasma
glucose concentration correlated significantly with an improvement
in the endothelium-related flow response to cold (r ¼ 0.46, P 
0.038; Figure 2C) and also with the change in hyperaemic flow
from rest during adenosine stimulation (r ¼ 0.36, P  0.05;
Figure 2D). We also evaluated the relationship between
glucose-lowering-induced alterations in structure and function of
the arterial wall in DM. We did not observe correlations between
changes in carotid IMT and MBF responses to CPT,DMBF to adeno-
sine, during adenosine stimulation, MFR, respectively (r ¼ 0.003,
P ¼ 0.99; r ¼ 0.07, P ¼ 0.76; r ¼ 0.11, P ¼ 0.67; and r ¼ 0.02, P ¼
0.93). Conversely, the alterations in CCS correlated significantly
with the endothelium-related increase in coronary flow to CPT
(r ¼ 0.53, P, 0.036) (Figure 3). Thus, the better the improvement
in endothelium-dependent coronary artery function, the lower
the progression of CCS. After adjusting for metabolic parameters
by multivariable analysis (Table 3), the increase in endothelium-
related DMBF to CPT after glucose-lowering treatment, apart
from alterations in SBP and triglycerides, remained statistically
significant independent predictors of the progression of CCS in
DM. The alterations in CCS after the 1-year FU, however, did not
correlate with changes in DMBF to adenosine, during adenosine
stimulation, and MFR, respectively (r ¼ 0.38, P ¼ 0.15; r ¼ 0.29,
P ¼ 0.28; and r ¼ 0.41, P ¼ 0.12).
Discussion
The results of the current study provide several novel obser-
vations. At first, glucose-lowering therapy in DM beneficially
Figure 1 Endothelium-related change in myocardial blood flow
(DMBF) to sympathetic stimulation with cold pressor testing in
controls and patients with type 2 diabetes mellitus at baseline
and follow-up.
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affected structural alterations of the vascular arterial wall. The
decrease in plasma glucose levels after a 1-year FU was associated
with a lower progression of CAC and carotid IMT, respectively.
These findings suggest direct adverse effect of elevated plasma
glucose levels on diabetes-related structural alterations of the vas-
cular wall. Glucose-lowering treatment in DM had also beneficially
altered coronary artery function as evidenced by a close corre-
lation between reductions in plasma glucose levels and an improve-
ment in coronary artery function. In particular, the improvement in
endothelium-related coronary artery function due to glucose-
lowering treatment in DM was independently associated with a
slowed progression of CAC. This observation is first of its kind
to denote indeed that an improvement in endothelium-dependent
coronary artery function in DM may mediate, at least in part, direct
preventive effects on the progression of diabetic vasculopathy, in
addition to that derived from glucose-lowering treatment.
Baseline examination of structure and
function of the arterial wall
As expected, hyperglycaemia in DM had not only induced early
structural alterations of the arterial wall, as denoted by an abnor-
mal increase in CAC and subintimal thickening of the carotid
artery, but also resulted in an abnormal functioning of the coronary
circulation. Structural abnormalities of the arterial wall, therefore,
were accompanied by diabetes-related early functional abnormal-
ities of the coronary circulation.9 Such abnormalities in coronary
Figure 2 (A) Correlation between the differences in Dlog-CCS (coronary calcium score) and in Dglucose decrease between baseline and
follow-up (negative values on the y-ordinate are indicative for a progression of coronary artery calcification). (B) Correlation between the differ-
ences in DIMT and in Dglucose decrease between baseline and follow-up (negative values on the y-ordinate are indicative for a progression of
carotid intima–media thickness). (C ) Correlation between the differences in DMBF to cold pressor testing and in Dglucose decrease between
baseline and follow-up. (D) Correlation between the differences in DMBF to adenosine stimulation and in Dglucose decrease between baseline
and follow-up.
Figure 3 Correlation between the differences in DMBF to cold
pressor testing and in Dlog-CCS (coronary calcium score)
between baseline and follow-up (negative values on the
x-ordinate are indicative for a progression of coronary artery
calcification).
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artery function may not only accompany but they may also
precede atherosclerotic disease-related structural alterations of
the arterial wall as also observed in the current and previous inves-
tigations.9 Increases in carotid IMT4,13 in the current DM popu-
lation were determined as a surrogate marker for subintimal
CAD process. This appears important as a negative EBT coronary
calcium study does not necessarily exclude the presence of ather-
osclerotic plaque burden but implies a very low likelihood of
significant luminal coronary artery obstruction.14 EBT measure-
ments of CAC compare well with those with multi-detector slice
computed tomography (MDCT) and are highly reproducible.11
Thus, both modalities allow an accurate and non-invasive quantifi-
cation of calcified areas of .2 mm2 and the resulting calcium
scores can be related to the extent and severity of CAD, while
it may also improve the cardiovascular risk prediction.5 When
EBT or MDCT identify CAC, it confirms the presence of coronary
atherosclerotic plaque disease. Notably, the greater the amount of
CAC, the greater is the likelihood of the presence of obstructive
CAD.14 Nevertheless, there is neither a one-to-one relationship
between the amount of CAC and obstructive CAD nor is it cite-
specific. Although EBT- or MDCT-measured CAC identifies ana-
tomical disease, it does not assess the downstream effect on myo-
cardial perfusion. Normal stress and rest N-13 ammonia PET
perfusion images in the current study population, however,
argued against the presence of haemodynamically significant
obstructive coronary artery lesions. Interestingly, a few study par-
ticipants of healthy CON had also some minor CAC. The reason
for this is unknown but may be related to age-dependent process
of atherosclerotic disease, unknown genetic factors, and/or over-
weight CON with insulin resistance.
Effects of glucose-lowering therapy
One year glucose-lowering treatment with glyburide or glyburide
in concert with metformin in DM beneficially affected structural
alterations of the arterial wall. As it was observed, decreases in
plasma glucose levels were correlated with a reduced progression
of CAC and carotid IMT, respectively. The observed close associ-
ation between the decrease in plasma glucose levels and the
slowed progression of vascular structural alterations indicates
that glucose-lowering treatment had directly prevented a further
progression of structural alterations of the arterial wall. Possible
mechanisms underlying this beneficial effect of glucose-lowering
treatment on diabetic vasculopathy may imply a reduction of a
continued accumulation of long-lived advanced glycation end pro-
ducts in the arterial wall, their interactions with advanced glycation
end products receptors, a reduced proliferation of vascular
smooth muscle cells and fibrous tissue, decreases in vascular
inflammation and oxidative stress burden, and as yet unknown vari-
ables.15 The decreases in plasma glucose concentrations in DM,
however, were not only correlated with a slowed progression of
structural alterations of the arterial wall, but also with an improve-
ment in endothelium-related coronary artery function, that is con-
sistent with own previous observations,7 and also with an increase
in total integrated coronary vasodilatory capacity. Possible mech-
anism underlying the improvement in coronary artery dysfunction
may comprise reductions in hypergylcaemia-stimulated
NADPH-oxidase with the formation of reactive oxygen species
and also an inactivation of protein kinase C associated with an
increase in the bioavailability of endothelium-derived and athero-
protective nitric oxide.1 Further, insulin secretagogues such as sul-
phonylureas or glyburide raise basal and postprandial insulin
secretion,7 which most likely has added to the improvement in
coronary artery function through insulin-stimulated release of
endothelium-derived derived nitric oxide. Conversely, metformin
lowers plasma glucose concentrations predominantly through its
insulin-sensitizing properties.7 Thus, the insulin-raising effect of gly-
buride and, at the same time, the metformin-mediated decrease in
insulin resistance may have directly enhanced the bioavailability of
endothelium-derived nitric oxide associated with an improvement
in coronary artery function. Notably, after adjusting for alterations
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Table 3 Determinants of alterations in log-CCS after glucose-lowering treatment
Differences in Difference in log-CCS
Univariate analysis Multivariable analysis
Coefficient b (95% CI) P-value Coefficient b (95% CI) P-value
DMBF to CPT (mL/g/min) 0.526 (0.050 to 1.305) 0.036 0.756 (0.472 to 0.590) 0.001
BMI (kg/m2) 0.229 (20.047 to 0.112) 0.393 — —
SBP (mmHg) 0.159 (20.006 to 0.011) 0.556 0.576 (0.004 to 0.006) 0.001
Glucose (mg/dL) 0.576 (0.000 to 0.004) 0.036 — —
Insulin (mU/mL) 20.195 (20.017 to 0.010) 0.544 — —
HOMA 20.345 (20.019 to 0.006) 0.298 — —
Total cholesterol (mg/dL) 0.117 (20.003 to 0.004) 0.667 — —
LDL cholesterol (mg/dL) 0.230 (20.003 to 0.006) 0.410 — —
HDL cholesterol (mg/dL) 0.278 (20.011 to 0.034) 0.298 — —
Triglycerides (mg/dL) 20.292 (20.003 to 0.001) 0.290 0.105 (0.000 to 0.000) 0.032
Free fatty acids (mg/dL) 0.396 (20.464 to 1.509) 0.257 — —
P-values by analysis of variance; CCS, coronary artery calcium score; MBF, myocardial blood flow; HOMA, homeostatic model assessment; SBP, systolic blood pressure; LDL
cholesterol, low-density lipoprotein cholesterol; HDL cholesterol, high-density lipoprotein cholesterol.
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in insulin-resistance, glucose, and lipids by multivariable analysis,
the improvement of endothelium-related myocardial flow
increases to CPT remained an independent predictor for the
slowed progression of CAC in DM. This observation provides
some first direct in vivo evidence that an improvement in
endothelium-dependent coronary artery function in DM may
indeed mediate, at least in part, direct preventive effects on the
progression of CAC. The causes for the mechanistic link
between the observed improvement in coronary endothelial func-
tion and the slowed progression of CAC in DM is certainly multi-
factorial but may be predominantly related to an enhanced
flow-mediated and, thus, endothelium-dependent release of nitric
oxide of the coronary circulation, implying numerous antithrombo-
tic and anti-atherosclerotic effects.2
Interestingly, the current investigation revealed a certain dis-
sociation of the responsiveness of the structure of the arterial
wall and of the function of the coronary artery to glucose-lowering
treatment in DM. The reasons for this remain uncertain but the
mild progression of structural atherosclerotic disease is most
likely related to suboptimal control of elevated glucose plasma
and, as yet unravelled, other pathophysiological mechanism
within the diabetic arterial wall. This consideration is substantiated
by recent pooled analysis of five intravascular ultrasound trials with
a total of 2237 coronary risk individuals evaluating the effect of DM
on progression of coronary atherosclerotic disease.15 Despite the
common application of standard preventive medical therapy, DM
was associated with a greater coronary atherosclerotic burden
and accelerated disease progression than in those cardiovascular
risk individual but without DM. The latter and current observations
may highlight the need for additional preventive medical therapy
strategies in DM, apart from euglycaemic control, such as
reductions in inflammation and oxidative stress burden within
the arterial wall aiming to prevent or halt the progression of dia-
betic vasculopathy and thereby to improve the cardiovascular
outcome.15 Further, it is also possible that coronary artery func-
tion, reflecting more ongoing processes that affect the functional
status of the arterial wall,2 responded more rapidly to glucose-
lowering treatment, whereas not so for diabetes-induced struc-
tural alterations of the arterial wall. As abnormalities in structure
and function of the arterial wall are considered as independent
predictors of future cardiovascular events in DM,2 an improvement
in coronary artery structure and, in particular, of its function, apart
from euglycaemic control, and/or behavioural interventions to
weight, diet, and physical activity, could emerge as a new specific
targets for primary preventive medical intervention to improve
the cardiovascular outcome that should be further tested.
Limitations
There are limitations to be considered in interpreting these data. In
the current investigation, 50% of DM had a combined therapy of
anti-diabetic medication. Thus, it remains uncertain to what
extent glyburide-mediated insulin increase and metformin-
stimulated insulin sensitivity had affected structure and function
of the arterial wall. For the baseline study, it can also be observed
that DM and CON were not perfectly matched for the age. As
atherosclerotic disease is also in part an age-dependent process,
we cannot exclude entirely that the age difference between both
groups at baseline studies may have mildly contributed to the
observed significant alterations in structure and function of the
arterial wall in DM when compared with CON. Further, in view
of the relatively small sample size of the study population, the
current clinical investigation does certainly not allow to draw defi-
nite conclusions but may stimulate further large-scale clinical trials
with sufficient long-term FUs to better define the role of non-
invasively determined subclinical markers of CAD to successfully
guide primary and secondary preventive medical intervention of
the CAD process.13
Conclusions
In DM, glucose-lowering treatment may beneficially affect struc-
ture and function of the vascular arterial wall, whereas the
observed improvement in endothelium-related coronary artery
function may also mediate direct preventive effects on the pro-
gression of epicardial structural disease.
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Mitral valve re-repair: correlating real-time three-dimensional intra-
operative transoesophageal echocardiography and surgical findings
Hector I. Michelena1* and Rakesh M. Suri2
1Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW., Rochester, MN 55905, USA and 2Division of Cardiovascular Surgery, Mayo Clinic, 200 First Street
SW., Rochester, MN 55905, USA
* Corresponding author. Tel.: þ1 507 284 3687, Fax: þ1 507 266 7929, E-mail: michelena.hector@mayo.edu
An 80-year-old male with prior mitral valve
repair presented with recurrent severe mitral
regurgitation. He had previously undergone
posterior mitral leaflet repair consisting of
leaflet resection and posterior annuloplasty
band in 1998 for Barlow’s disease with severe
mitral regurgitation. The patient presented with
NYHA class III– IV symptoms. Transthoracic
echocardiogram reported an ejection fraction
of 53% and anterior mitral leaflet prolapse with
posteriorly directed severe mitral regurgitation.
Intra-operative 2-D transoesophageal (TEE)
evaluation revealed intact previous repair and
new pathology consisting of a prolapsing
middle (A2) and medial (A3) scallops of the
anterior leaflet (white arrow-top row) generat-
ing a posterior-lateral jet of mitral regurgitation
with large convergence zone (black arrow-top
row). Real-time 3-D transoesophageal images
from the left atrial perspective revealed a large,
unsupported medial scallop (Panel A, asterisk,
arrows represent medial annuloplasty band
aspect) without flail and no further prolapsing
segments, corresponding precisely with surgical
findings (Panel B, asterisk, arrows denote
medial annuloplasty band aspect). A pair of
Gore-tex neochordae were inserted to the
medial scallop of the anterior leaflet (Panel C, arrow indicates neochordae suture-ends) and posterior-medial papillary muscle. Follow-
ing cardiopulmonary bypass, appropriate coaptation of medial scallops was confirmed by 3-D (Panel D, arrow indicates neochordae
suture-ends) with no residual mitral regurgitation. The patient did well postoperatively. In patients with myxomatous mitral disease,
the ability to identify the size and location of the prolapsing segments and their associated regurgitant jets are particularly useful for
planning surgical intervention, especially in case of re-repair where native anatomy can be obscured by prior repair, and a specific
goal-directed surgical strategy is required.
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